Thus, treating obesity and metabolic dysfunction by either systemic or endothelial-specific PHD2 inhibition may cause unwanted side effects such as cardiac dysfunction and increased mortality. The gene discussed is EGLN1; the disease is obesity due to melanocortin 4 receptor deficiency.